SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.
SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.
复制标题
DOI：
10.1016/j.cytox.2020.100029
复制
发表时间：
2020-06-01
期刊：
影响因子：
--
通讯作者：
Magro, Giuseppe
中科院分区：
文献类型：
--
作者：
Magro, Giuseppe
自 COVID-19 爆发以来，已发表的许多研究都显示了可能的治疗方法，本文作者讨论了疾病末期相关药物，例如目前用于 ARDS 患者的托珠单抗 (Tocilizumab)。在一些患者中，疾病进展导致细胞因子大量分泌，称为细胞因子风暴，其中IL-6发挥着重要作用。在这里，作者展示了 IL-6 如何具有促炎和抗炎特性，具体取决于转导途径：可溶性（反式信号传导）或膜相关性（经典信号传导），并提出如何使用 SGP130Fc 仅靶向促炎途径可能是比同时靶向这两种途径更好的选择。然后分析了其他可能的 IL-6 通路抑制剂，例如 Ruxolitinib 和 Baricinitib，了解它们为何缺乏仅针对促炎通路的益处。
Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.